On May 6, the FDA announced the expansion of unannounced inspections at foreign manufacturing facilities producing foods and medical products for U.S. consumers. This move follows a pilot program in India and China, seeking to level the regulatory field between foreign and domestic companies. Currently, the FDA conducts about 12,000 domestic inspections and 3,000 foreign inspections annually. Domestic inspections often occur without prior notice, but foreign companies frequently received advance notice, diminishing the effectiveness of oversight. The initiative seeks to reinforce consumer safety and maintain product integrity.
The FDA is set to enhance oversight by expanding unannounced inspections at foreign manufacturing facilities, ensuring equal scrutiny for domestic and foreign companies.
This expansion of inspections addresses the currently uneven regulatory practices, aiming to hold foreign firms accountable to the same standards as U.S. manufacturers.
Collection
[
|
...
]